ASP Isotopes (ASPI) Q4 2024 earnings summary

Executive summary

• Achieved a major milestone with the successful enrichment of Ytterbium-176 and commencement of commercial sample production.

• Three manufacturing plants (Carbon-14, Silicon-28, Ytterbium-176) started commercial production, overcoming technical and supply chain challenges.

• PET Labs generated $4.2 million in revenue for the year, with expectations for further growth due to recent investments.

Financial highlights

• Annual revenue reached $4.2 million, primarily from PET Labs.

• Carbon-14 plant secured a take-or-pay contract for a minimum of $2.5 million per year, with potential for higher sales.

• Ytterbium-176 pricing discussed at $20,000 per gram, with indicated demand for two kilograms.

• Silicon-28 orders are increasing, with ongoing discussions with multiple customers.

• Operating cash burn for the year was about $15 million, ending with $60 million in cash, providing four years of runway at current burn rates.

Outlook and guidance

• No formal revenue or earnings guidance provided for 2025.

• Free cash flow positive expected in the second half of the year if revenue targets are met.

• Plans to ramp up production of Ytterbium-176 and expand into new isotope plants (Nickel-64, Gadolinium-160, Lithium-6) pending permit approvals.

• Expansion into North America and the UK under consideration, likely through partnerships.